|
ИСТИНА |
Войти в систему Регистрация |
ФНКЦ РР |
||
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopeniasстатья
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 15 февраля 2024 г.
- Авторы: Nikitin Eugene, Kislova Maria, Morozov Dmitry, Belyakova Vera, Suvorova Anna, Sveshnikova Julia, Vyscub Galina, Matveeva Irina, Shirokova Maria, Shipaeva Anna, Klitochenko Tatyana, Makarovskaya Polina, Dmitrieva Elena, Biderman Bella, Sudarikov Andrei, Obukhova Tatyana, Samoilova Olga, Kaplanov Kamil, Konstantinova Tatyana, Mayorova Olga, Poddubnaya Irina, Ptushkin Vadim
- Журнал: Leukemia
- Том: 37
- Номер: 7
- Год издания: 2023
- Издательство: Nature Publishing Group
- Местоположение издательства: United Kingdom
- Первая страница: 1464
- Последняя страница: 1473
- DOI: 10.1038/s41375-023-01891-3
- Аннотация: Autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) are common complications of CLL. The optimal treatment of steroid refractory AIHA/PRCA is not well established. We conducted a multicenter study of ibrutinib and rituximab in patients with relapsed/refractory to steroids AIHA/PRCA and underlying CLL. Protocol included induction (ibrutinib 420 mg/day and rituximab, 8 weekly and 4 monthly infusions) and maintenance phase with ibrutinib alone until progression or unacceptable toxicity. Fifty patients were recruited (44—warm AIHA, 2—cold AIHA, 4—PRCA). After the induction 34 patients (74%) have achieved complete response, 10 (21.7%) partial response. Median time to hemoglobin normalization was 85 days. With regards to CLL response 9 (19%) patients have achieved CR, 2 (4%) patients—stabilization and 39 (78%)—PR. The median follow-up was 37.56 months. In AIHA group 2 patients had a relapse. Among 4 patients with PRCA 1 patient did not respond, and 1 patient had a relapse after CR, 2 remained in CR. The most common adverse events were neutropenia (62%), infections (72%), gastrointestinal complications (54%). In conclusion ibrutinib in combination with rituximab is an active second-line treatment option for patients with relapsed or refractory AIHA/PRCA and underlying CLL.
- Добавил в систему: Судариков Андрей Борисович